Tirapazamine Plus Cyclophosphamide in Treating Children With Refractory Solid Tumors
A Trial of Tirapazamine and Cyclophosphamide in Children With Refractory Solid Tumors
Přehled studie
Postavení
Intervence / Léčba
Detailní popis
OBJECTIVES:
I. Determine the maximum tolerated dose and the dose limiting toxicity of tirapazamine when administered with cyclophosphamide as intravenous infusions to children with refractory solid tumors.
II. Determine the incidence and severity of other toxicities of tirapazamine and cyclophosphamide in these patients.
III. Determine a safe and tolerable dose of tirapazamine administered with cyclophosphamide for a phase II study for the same indications.
IV. Determine the pharmacokinetics of tirapazamine in children and adolescents receiving the combination of tirapazamine and cyclophosphamide.
V. Determine the preliminary evidence of antitumor activity of tirapazamine and cyclophosphamide.
OUTLINE: This is a dose escalation study.
Patients receive tirapazamine by 2 hour intravenous infusion (hours 0-2) followed 2 hours later by a 30 minute intravenous infusion of cyclophosphamide. This course is repeated every 3 weeks in patients with partial/complete response or stable disease for a maximum of 1 year. Cohorts of 3-6 patients each are treated at each dose level of tirapazamine. Dose escalation of tirapazamine occurs when 0 of 3 patients or 1 of 6 patients has experienced dose limiting toxicity (DLT). If DLT is experienced in 1 of 3 patients at a given dose level, up to 3 additional patients are treated at that same dose level. If none of the 3 additional patients at that dose level experiences DLT, the dose is escalated. If DLT is experienced in 1 or more of the additional 3 patients, the maximum tolerated dose (MTD) has been exceeded and 3 patients are treated at the next lower dose level (defined as the MTD). A total of six patients are treated at the MTD. If DLT is proved to be neutropenia, patients must then also meet the additional eligibility criteria listed for stratum 2. If neutropenia continues to be the DLT in stratum 2, then additional patients receive subcutaneous filgrastim (granulocyte colony-stimulating factor; G-CSF) beginning 24 hours after cyclophosphamide. A second MTD may be determined for chemotherapy with G-CSF. Patients are followed every 6 months for 4 years, and then annually thereafter.
Typ studie
Zápis (Aktuální)
Fáze
- Fáze 1
Kontakty a umístění
Studijní místa
-
-
Ontario
-
Toronto, Ontario, Kanada, M5G 1X8
- Hospital for Sick Children
-
-
Quebec
-
Montreal, Quebec, Kanada, H3H 1P3
- Montreal Children's Hospital
-
Montreal, Quebec, Kanada, H3T 1C5
- Hopital Sainte Justine
-
-
-
-
Alabama
-
Birmingham, Alabama, Spojené státy, 35294
- University Of Alabama Comprehensive Cancer Center
-
-
Arkansas
-
Little Rock, Arkansas, Spojené státy, 72205
- University of Arkansas for Medical Sciences
-
-
California
-
La Jolla, California, Spojené státy, 92093-0658
- University of California San Diego Cancer Center
-
Palo Alto, California, Spojené státy, 94304
- Lucile Packard Children's Hospital at Stanford
-
-
Florida
-
Miami, Florida, Spojené státy, 33136
- Sylvester Cancer Center, University of Miami
-
-
Georgia
-
Atlanta, Georgia, Spojené státy, 30322
- Emory University Hospital - Atlanta
-
-
Illinois
-
Chicago, Illinois, Spojené státy, 60614
- Children's Memorial Hospital, Chicago
-
-
Kansas
-
Kansas City, Kansas, Spojené státy, 66160-7357
- University of Kansas Medical Center
-
-
Maryland
-
Baltimore, Maryland, Spojené státy, 21287
- Johns Hopkins Oncology Center
-
-
Massachusetts
-
Boston, Massachusetts, Spojené státy, 02115
- Dana-Farber Cancer Institute
-
Boston, Massachusetts, Spojené státy, 02111
- Floating Hospital for Children
-
-
Michigan
-
Detroit, Michigan, Spojené státy, 48201
- Children's Hospital of Michigan
-
-
Mississippi
-
Jackson, Mississippi, Spojené státy, 39216-4505
- University of Mississippi Medical Center
-
-
Missouri
-
Saint Louis, Missouri, Spojené státy, 63110
- Washington University School of Medicine
-
Saint Louis, Missouri, Spojené státy, 63104
- Cardinal Glennon Children's Hospital
-
-
New Jersey
-
Hackensack, New Jersey, Spojené státy, 07601
- Hackensack University Medical Center
-
-
New York
-
Buffalo, New York, Spojené státy, 14263-0001
- Roswell Park Cancer Institute
-
Syracuse, New York, Spojené státy, 13210
- State University of New York - Upstate Medical University
-
-
North Carolina
-
Durham, North Carolina, Spojené státy, 27710
- Duke Comprehensive Cancer Center
-
-
Tennessee
-
Memphis, Tennessee, Spojené státy, 38105-2794
- Saint Jude Children's Research Hospital
-
-
Texas
-
Dallas, Texas, Spojené státy, 75235-9154
- Simmons Cancer Center - Dallas
-
Fort Worth, Texas, Spojené státy, 76104
- Cook Children's Medical Center - Fort Worth
-
Houston, Texas, Spojené státy, 77030
- Baylor College Of Medicine
-
San Antonio, Texas, Spojené státy, 78284
- University of Texas Health Science Center at San Antonio
-
-
Wisconsin
-
Milwaukee, Wisconsin, Spojené státy, 53226
- Midwest Children's Cancer Center
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
DISEASE CHARACTERISTICS:
- Histologically confirmed solid tumor that is refractory to conventional therapy or for which no effective therapy is known
- Brain tumors eligible Brainstem gliomas may waive histological verification requirement
- Neurologic deficits associated with CNS malignancies must be stable for a minimum of 4 weeks prior to study
- No leukemia Stratum 2
- No marrow involvement
PATIENT CHARACTERISTICS:
- Age: 21 and under
- Performance status: Karnofsky or Lansky 50-100%
- Life expectancy: At least 8 weeks
- Absolute neutrophil count at least 1,000/mm3
- Platelet count at least 75,000/mm3
- Hemoglobin at least 9 g/dL
- Bilirubin less than 1.5 mg/dL
- SGPT less than 5 times normal
- Creatinine normal for age OR creatinine clearance at least 70 mL/min
- Shortening fraction at least 27% of normal OR ejection fraction greater than 50% of normal
- Not pregnant or nursing
- Negative pregnancy test required
PRIOR CONCURRENT THERAPY:
- No concurrent anticancer therapy
- At least 6 months since bone marrow transplant and no evidence of graft versus host disease
- At least 1 week since growth factors
- No concurrent granulocyte colony-stimulating factor
- Recovered from prior immunotherapy
- Stratum 2: No prior bone marrow transplantation (with or without total body irradiation)
- At least 6 weeks since prior nitrosourea
- At least 2 weeks since other prior myelosuppressive chemotherapy
- Dexamethasone must be a stable or decreasing dose for 2 weeks prior to study
- Recovered from prior chemotherapy
- Stratum 2: No more than 2 prior chemotherapy regimens
- At least 2 weeks since local palliative radiotherapy (small port)
- At least 6 months since prior substantial bone marrow radiation (e.g., cross- sectional radiotherapy [greater than 24 Gy], total body irradiation, hemi- pelvic radiotherapy)
- Recovered from prior radiotherapy
- Stratum 2: No prior central axis radiation
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: N/A
- Intervenční model: Přiřazení jedné skupiny
- Maskování: Žádné (otevřený štítek)
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Experimentální: Arm I
See arm description.
|
Spolupracovníci a vyšetřovatelé
Sponzor
Vyšetřovatelé
- Studijní židle: Victor Aquino, MD, Simmons Cancer Center
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia
Primární dokončení (Aktuální)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Odhad)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Odhad)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další relevantní podmínky MeSH
Další identifikační čísla studie
- NCI-2012-01837
- POG-9675
- CDR0000066219 (Identifikátor registru: PDQ (Physician Data Query))
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .